teamLab Planets in Tokyo Opens a Dining Experience, an Art Space, and a Flower Shop on October 8
teamLab Planets TOKYO in Toyosu, Tokyo welcomes “Vegan Ramen UZU Tokyo” from Kyoto; a new artwork space; and a flower shop where visitors can take home the orchids used in one of the museum’s artworks. “Vegan Ramen UZU Kyoto” opened in Kyoto in March of 2020, becoming hugely popular with hour-long wait times. At “Vegan Ramen UZU Tokyo,” vegan ramen can be enjoyed in the Reversible Rotation - Non-Objective Space or Table of Sky and Fire artwork spaces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210927005038/en/
Soy Sauce Vegan Ramen (Photo: Business Wire)
There will also be a new flower shop, “teamLab Flower Shop & Art,” where visitors can take home orchids used in the artwork Floating Flower Garden: Flowers and I are of the Same Root, the Garden and I are One, in which visitors become one with over 13,000 orchids. All of these facilities open on Friday, October 8 to the public, not just to teamLab Planets museumgoers.
Vegan Ramen UZU Tokyo : https://vegan-uzu.com/pages/uzu-tokyo-en
teamLab Planets Museum Details: planets.teamlab.art
teamLab Planets Highlight Video: https://youtu.be/xofyyJYYWMY
[Vegan Ramen UZU]
At "Vegan Ramen UZU Kyoto,” which opened in March of 2020 in Gosho-Minami, Kyoto, teamLab was responsible for designing the space and other aspects of the restaurant, where guests can enjoy vegan food while surrounded by art.
“Vegan Ramen UZU Tokyo,” which will open at teamLab Planets, will have vegan ramen available for takeout, as well as to enjoy at the newly-opened Reversible Rotation - Non-Objective Space and Table of Sky and Fire artwork spaces. Flower Vegan Ramen, Green Tea Vegan Ramen, and Vegan Ice Cream will also be available only at “Vegan Ramen UZU Tokyo.”
Official Website: https://vegan-uzu.com/
Media Coverage of “Vegan Ramen UZU Kyoto”
-
Time Out
“teamLab has designed a vegan ramen restaurant in Kyoto”
https://www.timeout.com/tokyo/news/teamlab-has-designed-a-vegan-ramen-restaurant-in-kyoto-012021
Vegan Ramen Menu
- Soy Sauce Vegan Ramen
- Miso Vegan Ramen (Spicy)
[Vegan Ramen UZU Tokyo Only Menu]
- Green Tea Vegan Ramen
- Flower Vegan Ramen (Cold)
[New Public Artworks]
Reversible Rotation - Non-Objective Space
teamLab, 2021, Digital Installation, Sound: Hideaki Takahashi
Artwork: https://planets.teamlab.art/tokyo/ew/reversiblerotation_nonobjective/
The artwork space is freed from the physical boundaries of the surfaces of tables or chairs.
The Spatial Calligraphy rotates in the artwork space, every aspect rotating in the same direction. But because of the special characteristics of Ultrasubjective Space, it can appear to be rotating clockwise or counterclockwise.
Spatial calligraphy is calligraphy drawn in space, a form of calligraphy that teamLab has been exploring since it was founded. The artwork reconstructs calligraphy in three dimensional space to express the depth, speed and power of the brush stroke, and that calligraphy is then flattened using the logical structure teamLab calls ultrasubjective space. The calligraphy shifts between two and three dimensions.
Table of Sky and Fire
teamLab Architects, 2021
Artwork: https://planets.teamlab.art/tokyo/ew/tableskyfire_planets/
This table reflects the sky and the Universe of Fire Particles Falling from the Sky. The table is connected to the artwork and to the sky.
Human beings need to be connected to the world to live. teamLab hopes that people will eat something on this table while thinking that to live and to eat is to stay connected to the world.
[teamLab Flower Shop & Art]
This is a flower shop where visitors can take home orchids used in the artwork Floating Flower Garden: Flowers and I are of the Same Root, the Garden and I are One (photo above), in which visitors become one with over 13,000 orchids.
Orchids live on even after the flowers have fallen, blooming again and again, sometimes for decades. In order for people to take home a part of the work, we sell tote bags containing a variety of orchids. Those who wish to purchase orchids separately may do so from a more limited selection of orchid species.
[teamLab Planets]
teamLab Planets is a museum where you walk through water, and a garden where you become one with the flowers. There are four massive exhibition spaces and two gardens.
By immersing the entire body with other people in these massive body immersive artworks, the boundary between the body and the artwork dissolves, the boundaries between the self, others, and the world become continuous, and we explore a new relationship without boundaries between ourselves and the world.
Enter barefoot, immerse your body with others in the artwork spaces, and become one with the world.
[Summary]
Vegan Ramen UZU Tokyo
https://vegan-uzu.com/pages/uzu-tokyo-en
Open Hours:
October
Mondays - Fridays 11:00 - 19:00
Saturdays 10:30 - 20:00
Sundays 10:30 - 19:00
Closed: same as closed days for teamLab Planets
teamLab Flower Shop & Art
Open Hours:
October
Mondays - Fridays 11:00 - 19:00
Saturdays 10:00 - 20:00
Sundays 10:00 - 19:00
Closed: same as closed days for teamLab Planets
teamlab Planets TOKYO
https://planets.teamlab.art/tokyo/
#teamLabPlanets
Term: July 7, 2018 - End of 2022
Venue: teamLab Planets TOKYO (6 Chome-1-16 Toyosu, Koto City, Tokyo)
Hours:
September: Mon - Fri 10:00 - 20:00 / Sat, Sun, Holidays 9:00-20:00
October: Mon - Fri 10:00 - 19:00 / Sat 9:00 - 20:00 / Sun 9:00 - 19:00
* Last entry 1 hour before closing
Closed: October 5
Admission:
[Entrance Pass]
Adults (ages 18 and older): JPY 3,200
University / Trade School Students: JPY 2,500
Middle School / High School Students: JPY 2,000
Children (ages 4 - 12): JPY 300
Infants (ages 3 and younger): Free
Seniors (ages 65 and older): JPY 2,400
Visitors with Disabilities: JPY 1,600
teamLab Planets TOKYO Ticket Store: https://teamlabplanets.dmm.com/en
* Admission and exhibition hours are subject to change. Please check the official website for the latest information.
* A separate admission fee is required for the newly-opened artwork space Reversible Rotation - Non-Objective Space. This space is also open to visitors other than teamLab Planets museumgoers.
Official Social Media Pages:
Instagram: https://www.instagram.com/teamlab.planets/
Facebook: https://www.facebook.com/TL.Planets/
Twitter: https://twitter.com/teamLabPlanets
Measures Against the Spread of COVID-19:
Infection prevention measures such as entry restrictions are being implemented. Please check the website for details.
https://teamlabplanets.dmm.com/en/covid-19
[Press Kit]
https://goo.gl/tQXMLm
[Media Inquiries]
https://goo.gl/forms/fqn8DmGV8WWIntP53
[PLANETS Co., Ltd.]
The managing entity for facilities operations at teamLab Planets TOKYO
Address: Tokyo Nihonbashi Tower 26F, 2-7-1 Nihonbashi, Chuo-ku, Tokyo
[About teamLab]
teamLab (f. 2001) is an international art collective, an interdisciplinary group of various specialists such as artists, programmers, engineers, CG animators, mathematicians and architects whose collaborative practice seeks to navigate the confluence of art, science, technology, and the natural world.
teamLab aims to explore the relationship between the self and the world and new perceptions through art. In order to understand the world around them, people separate it into independent entities with perceived boundaries between them. teamLab seeks to transcend these boundaries in our perception of the world, of the relationship between the self and the world, and of the continuity of time. Everything exists in a long, fragile yet miraculous, borderless continuity.
teamLab has been the subject of numerous exhibitions at venues worldwide, including New York, London, Paris, Singapore, Silicon Valley, Beijing, Taipei, and Melbourne among others. The permanent museums teamLab Borderless opened in Odaiba,Tokyo in June 2018, and teamLab Borderless Shanghai in Huangpu District, Shanghai in November 2019. teamLab Planets, a museum where you walk through water and a garden where you become one with the flowers in Toyosu, Tokyo is on view until the end of 2022. The large-scale permanent exhibition teamLab SuperNature soft opened in Macao in June, 2020. teamLab’s annual life-work exhibition, VOLVO teamLab: A Forest Where Gods Live, is on view in Mifuneyama Rakuen, Takeo Hot Springs, Kyushu until November 7, 2021.
teamLab’s works are in the permanent collection of the Museum of Contemporary Art, Los Angeles; Art Gallery of New South Wales, Sydney; Art Gallery of South Australia, Adelaide; Asian Art Museum, San Francisco; Asia Society Museum, New York; Borusan Contemporary Art Collection, Istanbul; National Gallery of Victoria, Melbourne; and Amos Rex, Helsinki.
teamLab is represented by Pace Gallery, Martin Browne Contemporary, and Ikkan Art.
teamLab: https://www.teamlab.art/
Instagram: https://instagram.com/teamlab/
Facebook: https://www.facebook.com/teamLab.inc
Twitter: https://twitter.com/teamLab_net
YouTube: https://www.youtube.com/c/teamLabART
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005038/en/
Contact information
Shusuke Sasahara
Public Relations, PLANETS Co., Ltd.
Email: pr-info@planets.art
Additional coverage: https://goo.gl/forms/fqn8DmGV8WWIntP53
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom